Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 7.33B |
| Revenue (ttm) | 39.21M |
| Net Income (ttm) | -311.35M |
| Shares Out | 81.64M |
| EPS (ttm) | -3.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 392,079 |
| Open | 89.24 |
| Previous Close | 91.35 |
| Day's Range | 87.19 - 91.00 |
| 52-Week Range | 19.45 - 103.00 |
| Beta | 2.30 |
| Analysts | Strong Buy |
| Price Target | 106.79 (+18.99%) |
| Earnings Date | Feb 26, 2026 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid... [Read more]
Financial Performance
In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $106.79, which is an increase of 18.99% from the latest price.
News
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expecte...
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
This Drugmaker's Stock Is Soaring Over 40% Monday
Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.
Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript
Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript
Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum
Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile,...
Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug.
The biopharma company is counting on KT-621 to treat patients with Type 2 inflammatory diseases.
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation fro...
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass.
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phas...
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript
Kymera Therapeutics, Inc. ( KYMR) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST Company Participants Jared Gollob - Chief Medical Officer Conference Call Participants Xiaochuan...
Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. ( KYMR) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Co-Founder, Presi...
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro...
Kymera Therapeutics, Inc. (KYMR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Direc...
Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Citi's 2025 Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jare...
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
The Best Small-Cap Stocks to Buy Now
Wall Street's best small-cap stocks to buy include biotech, real estate and software names.